2-hydroxy-3,3-dimethyl-butyric acid amide | 89584-19-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-hydroxy-3,3-dimethyl-butyric acid amide
• 英文别名: β.β.β-Trimethyl-milchsaeureamid；2-Hydroxy-3,3-dimethyl-buttersaeure-amid；2-Hydroxy-3,3-dimethylbutanamide
• CAS: 89584-19-0
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: GKXXUKDPZLHTBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲基丙酮酸 在 哌啶 、 硫酸 、 苯胺 作用下， 生成 2-hydroxy-3,3-dimethyl-butyric acid amide
  参考文献：
  名称：

  Richard, Annales de Chimie (Cachan, France), 1910, vol. <8> 21, p. 394

  摘要：

  DOI：

文献信息

• CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
  申请人：FLX Bio, Inc.

  公开号：US20180072743A1

  公开（公告）日：2018-03-15

  Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

  披露的内容包括但不限于，用于调节趋化因子受体活性的化合物及其使用方法。
• Antiinfective Lipopeptides
  申请人：Alexander Christopher Dylan

  公开号：US20080051326A1

  公开（公告）日：2008-02-28

  The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.

  本发明涉及新型脱氨肽类化合物。该发明还涉及这些化合物的药物组合物以及将这些化合物用作抗菌化合物的方法。该发明还涉及生产这些新型脱氨肽类化合物以及用于生产这些化合物的中间体的方法。
• Pyridazine derivatives and their use as therapeutic agents
  申请人：Chakka Nagasree

  公开号：US20060009459A1

  公开（公告）日：2006-01-12

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia): where x, y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明涉及一种治疗哺乳动物（优选为人类）SCD介导的疾病或病症的方法，其中所述方法包括向需要治疗的哺乳动物中给予式(Ia)的化合物，其中x、y、W、V、R2、R3、R4、R5、R6、R6a、R7、R7a、R8、R8a、R9和R9a如本文所定义。此外，本发明还涉及含有式(I)的化合物的制药组合物。
• Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135383A1

  公开（公告）日：2007-06-14

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

  本发明提供了治疗磷脂酶相关疾病的方法和组合物。具体地，本发明提供了一种用于治疗动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病的方法。该方法通常涉及在胃肠道腔中定位的非吸收和/或外流的磷脂酶A2抑制剂的给药。
• Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds
  申请人：Buysse M. Jerry

  公开号：US20080021049A1

  公开（公告）日：2008-01-24

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a phospholipase A2 inhibitor having comprising a substituted organic compound having a fused five-member ring and six-member ring, such as indole-containing compounds.

  本发明提供了治疗磷脂酶相关疾病的方法和组合物。特别地，本发明提供了一种治疗动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病的方法。该方法通常涉及到给动物主体注射一种含有融合的五元环和六元环的取代有机化合物的磷脂酶A2抑制剂，例如吲哚类化合物。